| scholarly article | Q13442814 |
| P356 | DOI | 10.1592/PHCO.26.3.333 |
| P698 | PubMed publication ID | 16503719 |
| P2093 | author name string | Nasser Chegini | |
| Xiaoping Luo | |||
| Issam Zineh | |||
| Richard S Schofield | |||
| Christopher B Arant | |||
| Timothy R Wessel | |||
| Gregory J Welder | |||
| Amy E Debella | |||
| P2860 | cites work | Structure and neutrophil-activating properties of a novel inflammatory peptide (ENA-78) with homology to interleukin 8 | Q24675647 |
| Atherosclerosis — An Inflammatory Disease | Q26776972 | ||
| Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) | Q27860959 | ||
| Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study | Q28186001 | ||
| Pravastatin suppresses the interleukin-8 production induced by thrombin in human aortic endothelial cells cultured with high glucose by inhibiting the p44/42 mitogen activated protein kinase | Q28362055 | ||
| Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm | Q29547181 | ||
| Inflammation in atherosclerosis | Q29547428 | ||
| Human endothelium as a source of multifunctional cytokines: molecular regulation and possible role in human disease | Q33544585 | ||
| New insights into the pharmacodynamic and pharmacokinetic properties of statins. | Q33832848 | ||
| Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines | Q34347054 | ||
| Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors | Q34432988 | ||
| Immune mechanisms in atherosclerosis | Q34462668 | ||
| Regulation of chemokine expression in atherosclerosis | Q35027759 | ||
| Clinical applications of granulocyte colony stimulating factor (G-CSF) | Q35337958 | ||
| Early vascular benefits of statin therapy | Q35574104 | ||
| Markers of inflammation and their clinical significance | Q36095131 | ||
| Hydroxymethylglutaryl coenzyme A reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with Chlamydia pneumoniae | Q37876716 | ||
| The heparin-binding (fibroblast) growth factor family of proteins | Q38286731 | ||
| Stimulation of inflammatory responses in vitro and in vivo by lipophilic HMG-CoA reductase inhibitors | Q40804462 | ||
| Statins do more than just lower cholesterol | Q41169571 | ||
| Regulation of interleukin-8 expression by HMG-CoA reductase inhibitors in human vascular smooth muscle cells | Q42525512 | ||
| The effect of statins on mRNA levels of genes related to inflammation, coagulation, and vascular constriction in HUVEC. Human umbilical vein endothelial cells | Q44134020 | ||
| Simvastatin reduces the expression of adhesion molecules in circulating monocytes from hypercholesterolemic patients. | Q44342175 | ||
| Hydroxymethylglutaryl coenzyme a reductase inhibitors down-regulate chemokines and chemokine receptors in patients with coronary artery disease | Q44437789 | ||
| Low-level endotoxin induces potent inflammatory activation of human blood vessels: inhibition by statins | Q44484464 | ||
| HMG-CoA reductase inhibitor, fluvastatin, has cholesterol-lowering independent "direct" effects on atherosclerotic vessels in high cholesterol diet-fed rabbits | Q44580461 | ||
| High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study | Q44585429 | ||
| Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells | Q44590321 | ||
| Atorvastatin reduces proinflammatory markers in hypercholesterolemic patients. | Q45110342 | ||
| Inhibitory effect of pitavastatin (NK-104) on the C-reactive-protein-induced interleukin-8 production in human aortic endothelial cells | Q45257699 | ||
| Changes in serum interleukin-6 and high-sensitivity C-reactive protein levels in patients with acute coronary syndrome and their responses to simvastatin | Q46411781 | ||
| Statins decrease Toll-like receptor 4 expression and downstream signaling in human CD14+ monocytes | Q46463155 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | endothelium | Q111140 |
| P304 | page(s) | 333-340 | |
| P577 | publication date | 2006-03-01 | |
| P1433 | published in | Pharmacotherapy | Q7180800 |
| P1476 | title | Modulatory effects of atorvastatin on endothelial cell-derived chemokines, cytokines, and angiogenic factors | |
| P478 | volume | 26 |
| Q43506581 | CXCL5 gene polymorphism association with diabetes mellitus |
| Q36420743 | CXCL5 polymorphisms are associated with variable blood pressure in cardiovascular disease-free adults |
| Q28385323 | Epithelial neutrophil-activating peptide (ENA-78), acute coronary syndrome prognosis, and modulatory effect of statins |
| Q35604131 | Ex vivo exposure of bone marrow from chronic kidney disease donor rats to pravastatin limits renal damage in recipient rats with chronic kidney disease |
| Q37700876 | Fenofibrate Attenuates Neutrophilic Inflammation in Airway Epithelia: Potential Drug Repurposing for Cystic Fibrosis |
| Q36073222 | Increased plasma levels of epithelial neutrophil-activating peptide 78/CXCL5 during the remission of Neuromyelitis optica. |
| Q42958893 | Statin Modulation of Human T-Cell Proliferation, IL-1β and IL-17 Production, and IFN-γ T Cell Expression: Synergy with Conventional Immunosuppressive Agents. |
| Q36695979 | Statins and the vascular endothelial inflammatory response |
| Q35222567 | The possible link between elevated serum levels of epithelial cell-derived neutrophil-activating peptide-78 (ENA-78/CXCL5) and autoimmunity in autistic children |
| Q37470209 | Update on statin-mediated anti-inflammatory activities in atherosclerosis |
Search more.